Understanding that communication and transparency from experts are critical enablers for widespread confidence in AI is the ...

The FDA has launched a review of clinical trials that plan to send American citizens' living cells to 'hostile' countries – ...

Cost and compliance may be colliding but, with the right strategy, organisations can navigate this intersection effectively.

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...

Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a treatment for metabolic ...

Grail is preparing to file for FDA approval of its Galleri test for detecting multiple cancers from a single blood test after ...

After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more ...

It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ...

BIO 2025 this year came at a uniquely fraught moment for vaccination in the United States just days after HHS Secretary ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

Skyclarys is an important growth product for Biogen, which has been hit in the last few years by a series of pipeline ...

Just a year ago, the GenAI buzz in pharma felt like the start of a gold rush. Leaders greenlit pilots. Teams spun up proof-of ...